Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) have earned a consensus recommendation of “Hold” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $4.81.
LIFE has been the topic of a number of research analyst reports. ValuEngine lowered shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating in a report on Thursday, September 14th.
Large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its holdings in shares of aTyr Pharma by 44.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after buying an additional 25,676 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of aTyr Pharma in the 3rd quarter valued at $455,000. Finally, Artal Group S.A. purchased a new stake in shares of aTyr Pharma in the 3rd quarter valued at $1,263,000. 58.28% of the stock is currently owned by hedge funds and other institutional investors.
aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. equities research analysts expect that aTyr Pharma will post -1.93 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “aTyr Pharma, Inc. (LIFE) Receives Average Rating of “Hold” from Analysts” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://baseballnewssource.com/markets/atyr-pharma-inc-life-receives-average-rating-of-hold-from-analysts/1822415.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.